Oxford Biomedica

News

Changes ring at Oxford Bio as ABL takeover talks progress

UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europ

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Zynteglo halt re-ignites viral vector safety concerns; analy...

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors

News

SparingVision raises €44.5m for retinitis pigmentosa gene th...

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease.

News

Sanofi hands back gene therapies to Oxford Biomedica

Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.

News